证券代码：688117 证券简称：圣诺生物 公告编号：2026-006 成都圣诺生物科技股份有限公司 关于自愿披露全资子公司取得药品生产许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都圣诺生物科技股份有限公司（以下简称"公司"）全资子公司眉山汇龙 药业科技有限公司（以下简称"眉山汇龙"）于近日收到四川省药品监督管理局 核准签发的《药品生产许可证》，现将相关情况公告如下： 质量负责人及质量受权人：霍金林 生产负责人：卢鹏 有效期至：2031 年 3 月 25 日 生产地址和生产范围：四川省眉山市东坡区眉山经济开发区新区本草大道北 段 15 号：原料药（仅限注册申报使用）*** 一、《药品生产许可证》的相关情况 企业名称：眉山汇龙药业科技有限公司 许可证编号：川 20260663 统一社会信用代码：91511402MA62J1372M 分类码：Dh 住所（经营场所）：四川省眉山市东坡区眉山经济开发区新区本草大道北段 15 号 法定代表人及企业负责人：曾德志 二、对公司的影响 眉山汇龙本次系首次取得《药品生产许 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2026-005 成都圣诺生物科技股份有限公司 部分董事、高级管理人员减持股份结果 减持计划的实施结果情况 2025 年 12 月 1 日，公司披露了《部分董事、高级管理人员减持股份计划公 告》（公告编号：2025-034），因个人资金需求，马中刚先生、伍利先生拟通过 集中竞价或大宗交易的方式减持其持有的公司股份。马中刚先生拟减持数量不超 过 18,816 股，即不超过公司总股本的 0.0120%，伍利先生拟减持数量不超过 1 18,816 股，即不超过公司总股本的 0.0120%，减持期间为减持计划公告披露之日 起 15 个交易日之后的 3 个月内。 公司于近日分别收到马中刚先生、伍利先生出具的《关于股份减持结果的告 知函》。截至 2026 年 3 月 22 日，马中刚先生、伍利先生未减持公司股份，本次 减持计划时间区间已届满。 暨未实施减持的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 部分董事、高级管理人员持有股份的基本情况 本 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2026-004 成都圣诺生物科技股份有限公司 关于自愿披露利那洛肽原料药获得上市申请 批准通知书的公告 登记号：Y20240000089 化学原料药名称：Linaclotide/利那洛肽 化学原料药注册标准编号：YBY62072026 包装规格：100g/瓶 申请事项：境内生产化学原料药上市申请 生产企业：成都圣诺生物制药有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品的其他情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、药品基本情况 成都圣诺生物科技股份有限公司（以下简称"公司"）全资子公司成都圣诺 生物制药有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 签发的关于利那洛肽原料药的《化学原料药上市申请批准通知书》，现将相关情 况公告如下： 三、对公司的影响 本次利那洛肽原料药获得上市申请批准通知书，将进一步丰富公司的原料药 1 产品 ...

Core Viewpoint - The company reported significant growth in its financial performance for the year 2025, driven by increased demand in the peptide drug market, particularly in the areas of glucose-lowering and weight-loss medications [2][4]. Financial Data and Indicators - The company achieved an operating income of 741.34 million yuan, representing a year-on-year increase of 62.55% [2]. - The net profit attributable to the parent company was 165.82 million yuan, up 231.49% from the previous year [2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 172.65 million yuan, reflecting a growth of 278.52% [2]. Financial Condition - As of the end of 2025, the total assets of the company amounted to 1.937 billion yuan, an increase of 17.55% compared to the beginning of the reporting period [3]. - The equity attributable to the parent company was 1.065 billion yuan, which is a growth of 16.02% from the start of the period [3]. Factors Influencing Operating Performance - The company's focus on the synergistic development of its core business in peptide drug CDMO, raw materials, and formulations has led to a significant increase in sales of GLP-1 raw materials, contributing to the substantial improvement in operating performance [4]. - The increase in total operating income, operating profit, total profit, and net profit attributable to the parent company, as well as the basic earnings per share, was primarily due to the company's proactive expansion of its raw material market both domestically and internationally [5]. Changes Exceeding 30% - The company experienced significant changes exceeding 30% in various financial metrics, attributed to the successful implementation of new production capacity and increased sales of semaglutide and teriparatide raw materials [5]. - The company's share capital increased by more than 30% due to a capital reserve conversion, resulting in an increase in the number of shares from 112,418,556 to 157,385,978 [5].

Core Viewpoint - Shengnuo Biotech (688117.SH) reported significant growth in its 2025 annual performance, driven by the increasing demand for peptide drugs in the global market, particularly in the areas of glucose reduction and weight loss [1] Financial Performance - The company achieved an operating revenue of 741 million yuan, representing a year-on-year increase of 62.55% [1] - The net profit attributable to the parent company reached 166 million yuan, marking a substantial year-on-year growth of 231.49% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 173 million yuan, reflecting a remarkable year-on-year increase of 278.52% [1] Business Focus - During the reporting period, the company maintained a strong focus on the synergistic development of its core businesses, including peptide drug CDMO, active pharmaceutical ingredients, and formulations [1] - The significant increase in sales of GLP-1 active pharmaceutical ingredients contributed to the substantial improvement in operational performance [1]

Group 1 - The core point of the article is that Shengnuo Bio announced significant financial growth for the year 2025, with total operating revenue reaching 741,343,445.99 yuan, representing a year-on-year increase of 62.55% [2] - The net profit attributable to the parent company's owners for the same period was 165,823,888.08 yuan, showing a remarkable year-on-year growth of 231.49% [2]

Financial Performance - The total operating revenue for 2025 reached RMB 741.34 million, an increase of 62.55% compared to the previous year[3] - The net profit attributable to the parent company was RMB 165.82 million, reflecting a growth of 231.49% year-over-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 172.65 million, up 278.52% from the previous year[3] - The basic earnings per share increased to RMB 1.05, a rise of 133.33% compared to the previous year[3] Assets and Equity - Total assets at the end of 2025 amounted to RMB 1,937.13 million, representing a growth of 17.55% from the beginning of the year[4] - The equity attributable to the parent company was RMB 1,065.50 million, an increase of 16.02% from the beginning of the year[4] Business Development - The company focused on the synergistic development of peptide drug CDMO, raw materials, and formulations, leading to a significant increase in sales of GLP-1 raw materials[7] - The increase in operating revenue and net profit was primarily driven by the expansion of domestic and international markets for raw materials, particularly for semaglutide and teriparatide[9] Share Capital - The company's share capital increased by 40% due to a capital reserve conversion, raising the total shares from 112,418,556 to 157,385,978[9] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[10]

Core Viewpoint - Shengnuo Bio reported significant growth in its financial performance for the fiscal year 2025, indicating strong operational momentum and profitability improvements [1] Financial Performance - The company achieved operating revenue of 741 million yuan, representing a year-on-year increase of 62.55% [1] - The net profit attributable to the owners of the parent company reached 166 million yuan, reflecting a substantial year-on-year growth of 231.49% [1] - The net profit attributable to the owners of the parent company, after deducting non-recurring gains and losses, was 173 million yuan, marking an impressive year-on-year increase of 278.52% [1]

Recent Events - The company announced on February 11, 2026, that its wholly-owned subsidiary, Chengdu Saintno Biological Pharmaceutical Co., Ltd., is participating in the national organized procurement of medicines, with multiple products (such as Acetate Octreotide Injection and Thymosin Alpha 1 Injection) expected to be selected. The results of the selection are anticipated to be officially implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028. This event may impact future sales scale and market share [2]. Performance and Operations - The company released a profit forecast on January 16, 2026, indicating a significant year-on-year increase in net profit attributable to the owners of the parent company. However, specific financial data will be confirmed in the subsequent audited annual report, the release date of which has not yet been announced. Attention should be paid to official communications from the company [3].

Industry Overview - Peptides are bioactive fragments of proteins that can be rapidly absorbed and utilized by the human body, providing energy and nutrients to cells. Their potential has been further released since the Human Genome Project in the 1990s, leading to unprecedented prosperity in peptide research and applications, especially in the pharmaceutical field [1][13] - The Chinese peptide industry market size is projected to grow from 57.34 billion yuan in 2016 to 209.12 billion yuan in 2024, with a compound annual growth rate (CAGR) of 17.56%. By 2025, the market size is expected to reach approximately 247.6 billion yuan [1][13] Market Segmentation - The peptide industry value chain consists of upstream raw materials and equipment (amino acids, amino acid protectants, resin acids, synthesis instruments, packaging materials), midstream production and manufacturing, and downstream applications in food, pharmaceuticals, feed, health products, and cosmetics [9][11] - The global peptide drug market is expected to reach approximately 96 billion USD by 2025, driven by the increasing prevalence of chronic diseases and the unique advantages of peptide drugs in treatment [12][17] Key Companies - HanYue Pharmaceutical focuses on four main areas: peptide formulations, raw materials, small nucleic acids, and CRDMO services. The company has achieved significant revenue growth, with a reported 114.86% increase in pharmaceutical manufacturing revenue in the first half of 2025 [20][21] - ZhongPeptide Biochemical Co., Ltd. specializes in contract research, development, and production of peptides and small nucleic acids, providing comprehensive services from early discovery to commercial production [21] Development Trends - The Chinese peptide industry is transitioning from traditional chemical synthesis to a deep integration of biotechnology and synthetic biology, enhancing production efficiency and reducing costs [22][24] - The application of peptides is rapidly expanding beyond pharmaceuticals into health, beauty, and functional food markets, with increasing consumer demand for personalized health solutions [23][24] - The industry is also moving towards green manufacturing and sustainable development, focusing on reducing environmental footprints and enhancing social responsibility [24]